03.08.2020 | Peritoneal Surface Malignancy
In Reference to Jonsdottir B et al. “The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer”
verfasst von:
Fabio Carboni, MD, PhD, Mario Valle, MD, FACS
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
We read with great interest the article by Jonsdottir et al.
1 on the role of Peritoneal Cancer Index (PCI) in Ovarian Cancer. The paper is well written, and we must compliment with authors for their outstanding experience in this field. Optimal cytoreductive surgery (CRS) is the mainstay for ovarian cancer treatment, because the presence of residual disease is the most important prognostic factor. If through assessment of tumor spread and performance status of the patient indicates that complete primary cytoreduction is not feasible without unacceptable morbidity, neoadjuvant chemotherapy (NACT) followed by interval debullking surgery (IDS) represents a valid alternative. …